Abstract
The coronavirus is one of the most unprecedented pandemics in recent decades. Countries have been struggling to identify the appropriate policies to prevent COVID-19 spread efficiently. As coronavirus case and death numbers fluctuated among countries in the past two years, questions of which policies are most cost-efficient and effective in preventing coronavirus spread have yet to be answered. There are no worldwide agreed guidelines to follow, to the author’s best knowledge. Countries are prone to making policy and implementation errors that could cost lives and cause tremendous economic loss. Although much research on COVID-19 has been done and many focused on policy effectiveness, few focused on the cost-efficiency and effectiveness of COVID-19 policies. This research identifies the most Cost-Efficient and Effective Set of COVID-19 Policies to Reduce Monthly COVID-19 Case Increase Rates through a quantitative, big-data-driven, and machine-learning enabled approach. The research collected and analyzed 13 COVID-19 policies and associated daily COVID-19 case numbers across 180 countries from January 2020 to June 2021, developed Policy Cost Model, defined Policy Efficiency and Effectiveness Index, and developed a Fully-Automated Best Policy Group Finder Python Program to find the most cost efficient and effective policy group. This research found that 1) Before Vaccinations are available, the most cost-efficient and effective policy group includes Facial Covering, Testing Policy, and Contact Tracing. Its cost-efficiency is a 1% monthly case decrease rate per billion of dollars spent. Its effectiveness is a 37% monthly case decrease rate. It is 1474 times more cost-efficient, 11 times more effective, and costs around $5336.83 Billion less than implementing all 12 common COVID-19 policies as the U.S. and many other countries did before vaccinations were available; 2) After Vaccinations are available, the most cost-efficient and effective policy group includes Facial Coverings, Contact Tracing, and Vaccinations. Its cost-efficiency is a 2.7% monthly case decrease rate per billion of dollars spent. Its effectiveness is a 52% monthly case decrease rate. It is 3835 times more cost-efficient, 21.5 times more effective, and costs around $5350 Billion less than implementing all 13 common COVID-19 policies as the U.S. and many other countries did. The research results will help countries, especially underdeveloped ones with very limited budgets, to identify and implement the most cost-efficient and effective policies so they can spend much less but reduce monthly cases much more.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
